Retrospective observational study in patients with renal cell carcinoma treated by everolimus, mTOR inhibitor

Trial Profile

Retrospective observational study in patients with renal cell carcinoma treated by everolimus, mTOR inhibitor

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Jan 2013

At a glance

  • Drugs Everolimus (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions
  • Most Recent Events

    • 17 Jun 2011 Planned end date changed from 1 Apr 2012 to 1 Sep 2012 as reported by University Hospital Medical Information Network - Japan.
    • 20 Dec 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top